Regina Gabitova

Vice President, Europe

Regina is a Vice President at CG Results Healthcare, having joined the firm in June 2019. She has approximately seven years of experience within corporate advisory and investment banking.

In previous roles, she focused on European transactions in the pharma, biotech and medtech space. She has been involved in a number of sale processes such as the sale of majority stake of Simbec Orion Group to CBPE, and the sale of Atopix to Chiesi; out-licensing transactions such as the licensing of ex-European rights for Lysogene’s orphan drug candidate LYS-SAF302 to Sarepta, the licensing of Shield’s Feraccru to Norgine in Europe, Australia and New Zealand, and the licensing of DBV Technologies’ paediatric milk allergy diagnostic to Nestle Health Sciences; and buyside processes including Midatech’s merger with US-listed oncology firm Dara Biosciences.

Regina holds a Masters Degree in Economics and Mathematics from University of St Andrews, Scotland. She is a native Russian speaker.

Growth for the sake of growth is the ideology of the cancer cell. - Edward Abbey

Latest Insights

30th May 2020

Biotech share prices in this COVID-19 era and the rollercoaster impact of remdesivir

Although the exact numbers are yet to be known, the virus has claimed nearly 220,000 lives and infected more than 3 million people globally. The COVID-19 outbreak is proving every week to be more of an economic event than a sanitary one. Numerous economic data releases from various countries every week are gloomy and prove […]

28th May 2020

The role of AI in defeating COVID-19

Given the ever-expanding scale and rapid speed at which coronavirus is spreading, the role of AI in defeating COVID-19 has become a focal point for the life sciences sector. Artificial intelligence (AI) tools used in healthcare are set to uncover possibilities for patients, doctors, and researchers, enabling them to make more informed decisions and achieve […]

20th May 2020

Moderna Coronavirus vaccine trial shows promising early results and the markets move positively

Every week is a roller coaster in the current COVID-19 environment. Most of us spend Sunday evenings preparing ourselves for the upcoming week and hoping for some positive developments on the healthcare, economy, or financial markets’ fronts. Luckily, on Monday, May 18th, Moderna’s coronavirus vaccine trial shed some light at the end of the tunnel […]

15th November 2019

Private equity appetite for the life sciences sector

Private equity firms are finding more creative ways to increase their investment in the life sciences sector.  Pharmaceutical researcher_private equity_life sciences sectorThe life sciences sector is a highly complex one comprising (often) subjective subsectors; Pharma including biotech, Pharma Services including med-comms and contract organisations and Medtech including medical devices and healthcare IT. Care services is […]